Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial
Catia Simoes(Navarre Institute of Health Research), Pau Montesinos(Instituto de Salud Carlos III), Esperanza Lavilla, David Martínez‐Cuadrón(Instituto de Salud Carlos III), Felipe Prósper(Institute of Human Genetics), Miguel Á. Sanz(Instituto de Investigación Sanitaria La Fe), Sara Villar(Hospital de Sant Pau), Jesús F. San Miguel(Clinica Universidad de Navarra), María-José Sayas(Hospital Universitario Doctor Peset), Jorge Labrador(Hospital Universitario de Burgos), José‐Francisco Falantes(Hospital Universitario Virgen del Rocío), Lorenzo Algarra(Hospital Universitari i Politècnic La Fe), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Cristina Gil(Hospital General Universitario de Alicante Doctor Balmis), Josefina Serrano(Instituto Maimónides de Investigación Biomédica de Córdoba), Pilar Herrera(Hospital Universitario Ramón y Cajal), Fernando Ramos(Hospital de León), Bruno Paiva(Navarre Institute of Health Research), Juan Bergua(Hospital San Pedro de Alcántara), María‐Belén Vídriales(Complejo Hospitalario de Salamanca), Rosa Ayala(Hospital Universitario 12 De Octubre), Susana Vives, Marı́a José Calasanz(Navarre Institute of Health Research), Pilar Martı́nez(Research Institute Hospital 12 de Octubre), J. López(Hospital Universitario Fundación Jiménez Díaz), Olga Salamero(Vall d'Hebron Institut de Recerca)
Cited by 25
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k